Navigation Links
Misonix Announces New Distribution Agreement for India
Date:11/14/2011

FARMINGDALE, N.Y., Nov. 14, 2011 /PRNewswire/ --- Misonix, Inc. (NASDAQ: MSON), a medical device company that designs, manufactures, and markets ultrasonic products worldwide for wound debridement, spinal surgery, cosmetic surgery, neurosurgery, laparoscopic and other surgical and medical applications, has entered into a new, four year, exclusive distribution agreement with Cure Surgicals, based in New Delhi, India, for the distribution of the SonaStar® Ultrasonic Surgical Aspirator and the BoneScalpel™ Ultrasonic Bone Cutter. The agreement provides Cure Surgicals with the right to sell throughout India. Included in the agreement are annual minimum purchase requirements.  Initial product training is complete and open market sales have begun.

Cure Surgicals has successful experience with launching state-of-the-art products and, in conjunction with Misonix, has begun holding physician training sessions throughout India aimed at acquainting the clinical community with the Company's unique technology.  Three of these meetings have been held to date, all in major cities, with more than 75 surgeons in attendance.

The SonaStar is used by Neuro and General Surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels.  In addition, OsteoSculpt™ bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.

The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures.  It offers the convenience and speed of a power instrument without the danger associated with rotary sharps.

"Misonix is excited to have Cure Surgicals representing our products in this large and important South Asian market.  Their reputation as an aggressive distributor of advanced medical devices in India is well known to us," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "Their approach to educating the Indian clinical community as to the value of therapeutic ultrasound technology mirrors that of Mixonix in other key markets..  We are particularly pleased that they will be selling two of our key products through their well established distribution network in India."

About Misonix:

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices.  Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies.  Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships,  regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  The Company disclaims any obligation to update its forward-looking relationships.

Investor Relations Contact:
Kevin McGrath/Cameron Associates, Inc.
212-245-4577
Kevin@cameronassoc.com


'/>"/>
SOURCE Misonix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Misonix Reports a 14.8% Increase in Revenue for the First Quarter Fiscal 2012 Financial Results
2. Misonix Schedules First Quarter Fiscal 2012 Financial Results Conference Call; November 9, 2011 at 4:30 p.m. Eastern
3. Misonix Announces its Exhibition at the European Association of Neurosurgical Societies
4. Misonix Exhibits at 26th Annual Clinical Symposium on Advances in Skin and Wound Care
5. Misonix Exhibits BoneScalpel™ at the International Meeting on Advanced Spine Techniques
6. Misonix Announces New Distribution Agreement for Austria, Germany & Switzerland
7. Misonix Announces the Sale of Its Laboratory and Forensic Safety Products Business for $1.5 Million
8. Misonix Reports Fourth Quarter and Year-End Fiscal 2011 Financial Results
9. Misonix Schedules Fourth Quarter and Year-End Fiscal 2011 Financial Results Conference Call; September 20, 2011 at 4:30 p.m. Eastern
10. Misonix Announces New Distribution Agreement for Australia and New Zealand
11. Misonix Announces Entry Into Surgical Wound Debridement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... 24, 2016 The innovator ... , s first dual therapy stent, introduces ... OrbusNeich, a global company specializing in the ... to include products to treat peripheral artery disease. The ... entry devices for lower limb and arteriovenous (AV) fistula ...
(Date:5/24/2016)... , May 24, 2016 Een ... verbindt, zodat zij collectief patiënten kunnen behandelen, hun kennis ... het idee achter de nieuwe en revolutionaire MDLinking App, ... de Nederlandse vaatchirurg dr. Hans Flu en oncologisch chirurg ... die inmiddels beschikbaar is, wordt op dinsdag 24 mei ...
(Date:5/23/2016)... , May 23, 2016 ... Market Size, Share, Development, Growth and Demand Forecast ... Single and Other), by Application (Drug Discovery and ... End Users (Pharmaceuticals, Life Science and Biotechnology, Academic ... P&S Market Research, the global mass spectrometry ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... Today Omega Institute, a leading destination ... innovative workshops and training opportunities in the growing field of yoga therapy ... who are dealing with specific health issues—including injuries, illnesses, and temporary or chronic health ...
(Date:5/25/2016)... ... May 25, 2016 , ... The Global Wellness Summit (GWS) today announced that ... offerings of Europe, a continent that pioneered the medical/wellness concept for the world. , ... in medical wellness, including Henri Chenot, Founder of the Chenot Group, which operates wellness ...
(Date:5/25/2016)... Harrisburg, PA (PRWEB) , ... May 25, 2016 ... ... today announced the results of its annual Medical and Prescription Drug survey ... health benefits. , The survey, which was conducted in December 2015, indicates ...
(Date:5/25/2016)... ... May 25, 2016 , ... Laser Skin & ... turn back the hands of time of female aging. The Juliet™ ... Women with symptoms such as leakage, laxity, itchiness and pain have reported real relief ...
(Date:5/25/2016)... ... 25, 2016 , ... Consumer access to organic foods and grower access to ... of whole grain cereals and other plant-based foods, will introduce the first consumer product ... wheat processed by Hesco/Dakota Organic Products. , The transitional designation means the cereal was ...
Breaking Medicine News(10 mins):